Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06374459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06374459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 30, 2025
Completion date
May 31, 2032
Enrollment
152 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive her-2 negative metastatic breast cancer